Cisplatin

Cancer centers in the United States continue to experience critical shortages of commonly used platinum-based chemotherapies, according to survey results from National Comprehensive Cancer Network.

In this video, Daneng Li, MD, a medical oncologist at City of Hope, discussed results from the phase 3 KEYNOTE-966 study, presented at American Association for Cancer Research Annual Meeting.

In this video, Ahmed Kaseb, MD, CMQ, discussed results from the phase 3 KEYNOTE-966 study, presented at American Association for Cancer Research Annual Meeting.

SAN FRANCISCO — The addition of atezolizumab to platinum-based chemotherapy failed to significantly improve survival for patients with metastatic urothelial carcinoma, according to a final analysis of the randomized phase 3 IMvigor130 trial.

SAN FRANCISCO — Neoadjuvant chemo-immunotherapy led to significant downstaging prior to definitive surgery for patients with muscle-invasive urothelial cancer, according to data presented at ASCO Genitourinary Cancers Symposium.

The FDA approved sodium thiosulfate to reduce risk for cisplatin-associated ototoxicity among certain children with cancer.

Weekly cisplatin appeared noninferior to an every-3-weeks dose as part of chemoradiotherapy regimen for certain patients with head and neck squamous cell carcinoma, according to study results presented during the ASCO20 Virtual Scientific Program.

De-escalation of treatment after two cycles of chemotherapy and a negative PET scan appeared safe and feasible among a cohort of men with low-volume metastatic seminoma, according to results of a phase 2 trial presented at Genitourinary Cancers Symposium.

A single course of adjuvant bleomycin, etoposide and cisplatin chemotherapy appeared safe and effective among a cohort of men with high-risk primary testicular cancer, according to results of the phase 3, single-arm, prospective 111 study published in European Urology.

Chemoradiotherapy significantly improved OS and failure-free survival compared with pelvic radiotherapy alone among women with high-risk endometrial cancer, according to results from the PORTEC-3 randomized phase 3 trial published in The Lancet Oncology.